Preferred Label : Reblozyl;
Origin ID : M000676598;
Related record
- See also inter- (CISMeF)
https://www.has-sante.fr/jcms/p_3281443/fr/reblozyl-luspatercept-syndrome-myelodysplasique-smd
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Reblozyl
luspatercept
myelodysplastic syndromes
anemia
adult
hematinics
luspatercept
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
injections
blood transfusion
Transfusion dependent anaemia
---
https://www.has-sante.fr/jcms/p_3281010/fr/reblozyl-25-ss-thalassemie-luspatercept
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
anemia
beta-Thalassemia
blood transfusion
Transfusion dependent anaemia
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
injections, subcutaneous
hematinics
luspatercept
evaluation of the transparency committee
luspatercept
Reblozyl
immunoglobulin fc fragments
recombinant fusion proteins
activin receptors, type ii
---
